Trump announces nine voluntary drug pricing agreements with mid-size biotech firms

On August 31, 2026, the White House announced that President Donald Trump has secured nine new voluntary drug-pricing agreements with mid-size biotechnology companies.

The companies entered the deals to avoid potential industry tariffs and to stay out of two CMS pilot programs that are being reviewed and could impose additional financial pressures.

By agreeing to set prices under the terms outlined by the administration, the firms hope to maintain market stability while the government seeks to control prescription-drug costs.

The agreements, described as "most favored nation" arrangements, are part of a broader effort by the administration to engage the pharmaceutical sector in voluntary pricing reforms.